UNITED EUROPEAN GASTROENTEROLOGY LES JOURNAL LES JOURNA

October 2021

Volume 9, Issue 8

SSN 2050-6406 (Print) ISSN 2050-6414 (Online)

onlinelibrary.wiley.com/journal/20506414



Find out more at ueg.eu/journal/

WILEY



UEG Week 2021

Table of Contents

UEG Week 2021 Oral Presentations

Sunday,	October	3,2021
---------	---------	--------

Towards a better understanding of dyspepsia		intestinal patnophysiology	81
and gastroparesis to improve therapeutic management	8	IBS	84
Challenges in clinical pancreatology	11	Endoscopic treatment of upper GI neoplasia	88
Advances in cirrhosis	14	IBD: Clinical trials III	92
IBD: Clinical trials I	17	Improving the understanding of oesophageal sensitivity and motility	98
Patient outcomes in IBD trials	21	Improving the outcome of acute pancreatitis	101
Management of duodenal tumors: All you want to know!	26	Liver diseases: From bench to bedside	104
Endoscopic diagnosis of oesophageal neoplasia	29	Pancreatic diseases: From bench to bedside	107
Advanced endoscopic therapy in lower GI	32	Endoscopic management of hereditary and inflammatory conditions	109
IBD: Clinical trials II (small molecules)	34		
Basic science in IBD	40	Tuesday, October 5, 2021	
Biomarkers and basic concepts in lower GI oncology	43	IBD drug efficacy and safety	112
Gastric and oesophageal preneoplastic lesions: Diagnosis and treatment	46	Innovation in biliopancreatic endoscopy	118
IBD prediction and prognosis	49	Gastric cancer spreading: What are the risks?	120
H.pylori: Extra-digestive manifestations and therapy	52	Endoscopy and surgery outcomes	123
		Diet, microbiota & more	127
Monday, October 4, 2021		Eosinophilic oesophagitis: The essential	130
IBD diagnostics and biomarkers	56	Prevention and management of bile stone disease	135
		Advanced imaging for GI neoplasia	138
A 360° look on lower GI oncology	60	IBD: Clinical trials IV	140
Diverse intestinal disorders	63	Safety and outcomes of interventions in IBD	146
Endoscopy on a different track	66	Novelties on oesophageal cancer:	
Clinical hepatology: Evolving issues	68	From diagnosis to treatment	151
IBD epidemiology and drug safety	74	Biomarkers in liver diseases	154
Microbiota in IBD	78	Video case session	158

Vol. 9 | October 2021

UEG Week 2021 Moderated Poster Presentations

UEG Week 2021 Poster Presentations

		Oesophageal, gastric and duodenal disorders	262
Sunday, October 3, 2021		H. pylori	314
IBD: Cross-sectional	164	Small intestinal	338
Basic aspects of GI neoplasia	168	Nutrition	366
Pancreatic cancer	172	IBD	386
Biliopancreatic endoscopy	175	Other lower GI disorders	588
IBD: Basic pathophysiology	178	Liver & biliary	648
Novel insights in a new disease: Eosinophilic oesophagitis	182	Pancreas	726
Acute and chronic pancreatitis	188	Endoscopy and imaging	766
Advanced endoscopy	191	Surgery	872
Health economical aspect in GI disorders	194	COVID-19	882
		Health economics / Digitalisation in GI / Education In GI / Gender and diversity	898
Monday, October 4, 2021			
IBD: Clinical trials poster I	197	Author Index	908
Upper GI bleeding	202		
Diseases of the bile duct	206		
Advanced Imaging for screening colonoscopies	209		
IBD: Clinical trials poster II	212		
Oesophageal motility	217		
Aspects of cirrhosis	220		
Outcomes in endoscopy	223		
Tuesday, October 5, 2021			
Lower GI malignancies	227		
Functional gastroduodenal disorders	232		
Hepatology: Disease mechanisms	236		
Colorectal neoplasia: Characterisation and treatment	240		
News in IBS	244		
Clinical aspects of upper GI malignancy	248		
Hepatology update	251		
Colon and small bowel endoscopy	254		

P0203

NATIVE AND SATURATED BOVINE LACTOFERRIN MODULATE THE EXPRESSION OF TOLL-LIKE RECEPTORS (TLRS) IN MICE TREATED WITH ANTIBIOTICS

<u>A. Bellés</u>^{1,2}, D. Aguirre-Ramírez¹, I. Abad^{2,3}, L. Sánchez^{2,3}, L. Grasa^{2,1,4}

¹Universidad de Zaragoza (Facultad de Veterinaria), Departamento de Farmacología, Fisiología y Medicina Legal y Forense, Zaragoza, Spain, ²Instituto Agroalimentario de Aragón IA2 (UNIZAR-CITA), Zaragoza, Spain, ³Universidad de Zaragoza (Facultad de Veterinaria), Departamento de Producción Animal y Tecnología de los Alimentos, Zaragoza, Spain, ⁴Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain

Contact E-Mail Address: a.belles@unizar.es

Introduction: The gut microbiota plays a fundamental role in protection against pathogen infections but also in the regulation of the immune system. The antibiotic administration can result in gut microbiota alterations and changes in the effectiveness of innate immune responses. As microbiota composition changes, the altered community will present different microbial-associated molecular patterns to Toll-like receptors (TLRs), which can cascade down through various immune responses, including changes in the expression of TLR receptors [1].

In this context, finding ingredients that can modulate the immune system is becoming a major focus of interest to produce functional foods. Bovine lactoferrin is a milk protein with many biological properties, including antibacterial and immunomodulatory activity [2].

Aims & Methods: The objective was to determine the effects of native (nLf) and saturated (sLf) bovine lactoferrin on TLR receptor expression of colon from mice treated or untreated with the antibiotic clindamycin, to evaluate its potential to be added in functional foods.

Male C57BL/6 mice of 8 weeks old were randomly divided into six groups (n=5 per group): vehicle, clindamycin (Clin), native bovine lactoferrin (nLf), nLf + clindamycin (nLf_Clin), iron-saturated bovine lactoferrin (sLf) and sLf + clindamycin (sLf_Clin). Vehicle received saline orally for 10 days. Clin was gavaged for 10 days with saline and on day 4 received a single IP injection of 200 μg of clindamycin. nLf and sLf were gavaged for 10 days with 35 mg of nLf or sLf. The groups nLf_Clin and sLf_Clin were gavaged with nLf or sLf and on day 4 received an injection of clindamycin.

The gene expression (mRNA) of TLR1-9 receptors was determined in the colon from mice by RT-PCR and relative expression levels of genes were calculated using the $2^{-\Delta\Delta CT}$ method.

Results: The expression of TLR2, TLR4, TLR5 and TLR6 was not modified in any of the treated groups. The expression of TLR1 was increased in sLf, nLf_Clin and sLf_Clin treated groups, indicating that the effect of sLf on TLR1 expression was maintained despite the treatment with Clin. The expression of TLR8 and TLR9 decreased in Clin, nLf and nLf_Clin groups. However, the levels of these receptors in sLf_Clin were similar to Vehicle, demonstrating the immunomodulatory capacity of sLf to restore these receptor levels, in a situation of intestinal dysbiosis.

Finally, respect to TLR3 and TLR7, only the group of mice treated with sLf_Clin showed an increase in the expression of this receptor.

Conclusion: Saturated bovine lactoferrin can restore the expression levels of TLR8 and TLR9 in conditions of intestinal dysbiosis induced by antibiotics.

These results confirm the immunomodulatory properties of lactoferrin, which have great interest for the design of functional foods.

References: 1. Grasa, L., et al., *Antibiotic-Induced Depletion of Murine Microbiota Induces Mild Inflammation and Changes in Toll-Like Receptor Patterns and Intestinal Motility.* Microb Ecol, 2015. **70**(3): p. 835-48.

2. Garcia-Montoya, I.A., et al., *Lactoferrin a multiple bioactive protein: An overview.* Biochimica Et Biophysica Acta-General Subjects, 2012. **1820**(3): p. 226-236.

Disclosure: Nothing to disclose.

P0204

ASSESSMENT OF GUT MICROBIOTA IN IBS PATIENTS AFTER A 4-WEEK STARCH-AND SUCROSE-REDUCED DIET SHOWS INCREASED BETA DIVERSITY, UNALTERED ALPHA DIVERSITY AND SPECIFIC CHANGES IN GENERA

C. Nilholm¹, L. Manoharan², B. Roth³, B. Ohlsson¹

¹Lund University, Department of Clinical Sciences, Malmö,

Sweden, ²Lund University, National Bioinformatics Infrastructure

Sweden (NBIS), SciLifeLab, Department of Laboratory Medicine,

Lund, Sweden, ³Skåne University Hospital, Department of Internal

Medicine, Malmö, Sweden

Contact E-Mail Address: claranilholm@gmail.com

Introduction: We have previously reported that IBS patients exhibit improved gastrointestinal (GI) symptoms following a starch- and sucrose-reduced diet (SSRD)¹. We aimed to examine the effect of the diet on gut microbiota.

Aims & Methods: IBS patients were randomized to a 4-week SSRD intervention (n=80) or control group (n=25); habitual diet). At baseline and 4 weeks, fecal samples and 4 day-dietary records were collected, and participants filled out GI symptom questionnaires, i.e., the VAS-IBS, IBS-SSS and Rome IV questionnaires. DNA was extracted from the fecal samples and analyzed through 16S rRNA gene amplicon sequencing, from the variable regions v1-v2.

Results: Seven different phyla were identified. The most dominant phyla in the intervention and control group both pre- and post-intervention were Bacteroidetes (relative abundance 55-60%) and Firmicutes (28-32%). The most notable change in phyla distribution during the intervention was an increase in the relative abundance of Proteobacteria in the intervention group, from 6.8% to 11.0%. There were no significant changes in alpha diversity in either group following the SSRD intervention. Beta diversity increased significantly in the intervention group (Permanova, p<0.001), but not in controls (data not shown). Specific genera, including the Eubacterium eligens group, Lachnospiraceae UCG-001, Lachnospira and Enterobacter increased significantly in the intervention group (log2 fold change: Eubacterium eligens group: 3.1; Lachnospiraceae UCG-001: 2.2, Lachnospira: 1.6 and Enterobacter: 1.4; p<0.001 for all). Weak correlations were identified between decreases in starch, carbohydrate and disaccharide intakes and increased beta diversity in the intervention group (table 1). No correlations could be identified between changes in beta diversity and total IBS-SSS or individual GI symptom scores.

Nutrient	\mathbb{R}^2	p
Protein (E%)	0.0660	0.009
Carbohydrates (g)	0.0491	0.028
Starch (g)	0.0681	0.013
Starch (E%)	0.0451	0.025
Disaccharides (g)	0.0577	0.014

E%= energy percentage. g=gram. Permanova. R^2 = correlation coefficient. p < 0.05 was considered significant.

Table 1. Correlations between change in beta diversity and changes in nutrient intakes in the intervention group